You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK (GenomeWeb) – A report last week authored jointly by researchers from the American Society for Clinical Oncology and the College of American Pathologists has put a damper on what some view as an overenthusiasm around liquid biopsy tests.
Premium Access gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.
This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.
In non-small cell lung cancer (NSCLC), liquid biopsy allows detection of driver mutations and can shed light on the development of resistance mutations during treatment.